Who has been buying Cell Biotech stock?

4 distinct insiders have filed 8 disclosed insider purchases in Cell Biotech (049960), most recently on 2025-12-02. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.

How many insider filings does Cell Biotech have?

Cell Biotech has 8 buy-side and 3 sell-side disclosures on record, covering ₩869M ($603K) in total reported value, spanning 2024-03-29 to 2025-12-02.

Do insider buys in Korean stocks predict returns?

Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Cell Biotech 049960

Company

쎌바이오텍Cell Biotech

Insiders

Buys

Total Value

₩869M ($603K)

Avg Return

+10.81%

Last Filing

2025-12-02

Cell Biotech (049960) has 8 disclosed insider purchases and 3 disclosed disposals on record, filed by 4 distinct insiders. Together those filings cover ₩869M ($603K) in reported transaction value. The earliest filing StockDrifts holds for Cell Biotech is dated 2024-03-29; the most recent is 2025-12-02. Across these filings the average return since disclosure is +10.81%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

Date	Type	Source	Insider	Position	Shares	Price at filing	Return	Value
2025-12-02	BUY	Market Buy	윤영옥 Youngok Yoon	moving	16.3K	₩14,330	+7.6%	₩233M ($162K)
2025-11-27	BUY	Market Buy	윤영옥 Youngok Yoon	moving	15.8K	₩13,100	+17.7%	₩207M ($144K)
2025-11-26	BUY	Market Buy	윤영옥 Youngok Yoon	moving	18.2K	₩13,080	+17.9%	₩238M ($165K)
2025-11-25	BUY	Market Buy	윤영옥 Youngok Yoon	moving	4.2K	₩12,850	+20.0%	₩54M ($37K)
2025-11-24	BUY	Market Buy	윤영옥 Youngok Yoon	moving	4.0K	₩12,790	+20.6%	₩51M ($35K)
2025-11-21	BUY	Market Buy	윤영옥 Youngok Yoon	moving	1.6K	₩12,810	+20.4%	₩20M ($14K)
2025-03-30	BUY	신규선임	정혜지 Hyeji Jeong	implementation	42.6K	₩12,590	+22.5%	₩536M ($372K)
2025-03-30	BUY	신규선임	정유숙 Yoosuk Jeong	moving	42.6K	₩12,590	+22.5%	₩536M ($372K)
2025-03-30	BUY	신규선임	송수근 Song Soo Geun	Outside Director	5.9K	₩12,590	+22.5%	₩74M ($51K)
2025-02-10	BUY	Market Buy	이상훈 Lee Sang-hoon	moving	100	₩13,910	+10.9%	₩1M ($966)
2025-02-03	SELL	Market Sell	윤성배 Seongbae Yoon	Managing Director	-2.6K	₩14,190	-8.7%	₩37M ($26K)
2025-01-22	SELL	Market Sell	윤성배 Seongbae Yoon	Managing Director	-209	₩14,150	-9.0%	₩3M ($2K)
2025-01-06	SELL	Market Sell	윤성배 Seongbae Yoon	Managing Director	-1.0K	₩14,380	-7.2%	₩14M ($10K)
2024-03-29	BUY	Market Buy	은유민 Yumin Lee	moving	817	₩11,970	+28.8%	₩10M ($7K)

Frequently asked questions

Who has been buying Cell Biotech stock?: 4 distinct insiders have filed 8 disclosed insider purchases in Cell Biotech (049960), most recently on 2025-12-02. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Cell Biotech have?: Cell Biotech has 8 buy-side and 3 sell-side disclosures on record, covering ₩869M ($603K) in total reported value, spanning 2024-03-29 to 2025-12-02.
Do insider buys in Korean stocks predict returns?: Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

More on this data

Every trade listed above comes from an official regulatory disclosure. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.